Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
2008

Rosiglitazone's Effect on Blood Pressure in Type 2 Diabetes

Sample size: 759 publication Evidence: moderate

Author Information

Author(s): Komajda Michel, Curtis Paula, Hanefeld Markolf, Beck-Nielsen Henning, Pocock Stuart J, Zambanini Andrew, Jones Nigel P, Gomis Ramon, Home Philip D

Primary Institution: Université Pierre et Marie Curie Paris 6; Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France

Hypothesis

Does adding rosiglitazone to metformin or sulfonylureas lower blood pressure more effectively than using metformin and sulfonylureas together in people with type 2 diabetes?

Conclusion

Adding rosiglitazone to metformin or a sulfonylurea significantly reduces ambulatory blood pressure compared to the combination of metformin and sulfonylureas.

Supporting Evidence

  • Rosiglitazone significantly reduced 24-hour ambulatory systolic blood pressure compared to metformin.
  • The reduction in diastolic blood pressure was also significant with rosiglitazone compared to sulfonylureas.
  • No compensatory increase in heart rate was observed with rosiglitazone treatment.

Takeaway

This study found that taking rosiglitazone with other diabetes medications helps lower blood pressure better than just using the other two medications together.

Methodology

Participants were randomized to receive either rosiglitazone or a comparator medication while continuing their existing diabetes treatment, with blood pressure monitored over 12 months.

Potential Biases

Potential bias due to the open-label design and the possibility of participant or physician preference affecting treatment adherence.

Limitations

The study was open-label, which could introduce bias, and background antihypertensive therapies could be modified during the study.

Participant Demographics

Participants were aged 40-75 years, predominantly Europid, with a mean age of around 57 years and a high prevalence of hypertension.

Statistical Information

P-Value

0.015

Confidence Interval

95% CI 0.5–4.9

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1475-2840-7-10

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication